RuiXin Medical Launches Global Expansion with Flagship Product RuiXin-FFR Entering Hong Kong Market

Recently, RaysightMed's product Raysight ScoreRaysightMed-FFR officially enters the Hong Kong market,And has begun to be put into use in Hong Kong hospitals.，Marks a milestone breakthrough in the company's road to global expansion.。

Hong Kong media reported that RaysightMed's RuiXin-FFR has brought a major breakthrough in the diagnosis of coronary heart disease.. At the same time, the media interviewedHonorary Associate Professor of The Chinese University of Hong Kong, Director of Hong Kong Asian Heart Center,Founder of the Hong Kong Structural Heart SocietyDr. Lin Yixian,He believes that the advantage of CT-FFR lies in reducing unnecessary invasive examinations and surgeries, and lowering the risk of surgical complications.

Innovativeness and Clinical Application Value Lead the Industry

RaysightMed ScoreRuiXin-FFRA precise, non-invasive, and integrated platform for assessing coronary blood supply function that combines morphology and functional studies, based on the coronary arteries.CT Angiography (CTA) image data, through artificial intelligence and three-dimensional computational fluid dynamics (3D-CFD) technology, performs three-dimensional reconstruction of coronary vessels and provides high-precision calculation results of Fractional Flow Reserve (FFR).Non-invasive assessment accurately evaluates the impact of coronary stenosis on myocardial blood supply, significantly improving the accuracy and efficiency of coronary heart disease diagnosis.。

RuiXin-FFR Operation Interface by RaysightMed

Recently, RaysightMed released the upgraded version of Rui Xin Score.RuiXin-FFR Version 2.0,Achieved fully automatic CT-FFR analysis, using all-new intelligent simulation to replace traditional 3D simulation, significantly reduces human involvement, ensures the high efficiency and high pass rate of the processing workflow, and outputs highly reliable results. The system introducesNew Generation Intelligent Interaction Interface, equipped with a wealth of semi-automatic auxiliary editing tools, achieves intelligent and efficient operation while being more compatible with standard computers in radiology departments. It also fully optimizes the quality inspection process. In addition, RuiXin-FFR 2.0Added key lesion parameters such as △FFR, APS, and WSS., which can accurately evaluate the development and rupture risk of coronary artery plaques from multiple dimensions, while also supporting clinical applications and scientific research.

With its outstanding performance in the field of cardiovascular disease assessment, RaysightMed ScoreRuiXin-FFR has received numerous authoritative certifications and honors both in China and internationally. Notably, RaysightMed's RuiXin-FFR isThe World's First "Morphology + Function" Coronary Blood Supply Function Assessment Platform with Dual Certification from China NMPA and EU CE, ensuring product quality aligns with international standards. Meanwhile, RuiXin-FFRIncluded in the NMPA Innovative Medical Device Excellence Catalog, demonstrating its leading position in innovation and clinical application value. Not only that, the product alsoEnjoyed the priority approval green channel for medical devices from the National Medical Products Administration`, reflecting the regulatory authority's high recognition of the advanced technology and market demand for RaysightMed's RuiXin-FFR.`

Launch Globalization Strategy, Accelerate Market Expansion

Hong Kong, as a forefront base for medical technology in Asia and even globally, boasts an open market environment and an advanced healthcare system, providing a solid foundation for RaysightMed's international expansion. The successful entry into the Hong Kong market this time not only serves as an international validation of the technical strength of RuiXin-FFR but also marks a significant milestone in RaysightMed's global strategy.This technology has not yet become widespread in Hong Kong, and currently, it is only available through private testing centers and private hospitals. Hong Kong citizens may face waiting times of up to a year for coronary intervention surgery in public hospitals.RuiXin-FFRAble to assist hospitals in accurate triage, identify patients who need priority surgery, and effectively reduce the burden on the public healthcare system.。In Hong Kong, RaysightMed will establish in-depth cooperative relationships with multiple well-known medical institutions and industry partners to jointly promote the clinical application of RuiXin-FFR, bringing intelligent, efficient, convenient, and cost-effective diagnosis and treatment experiences to more patients with cardiovascular diseases.

The successful entry into the Hong Kong market marks an important step in RaysightMed's global strategy. Moving forward, the company will continue to uphold"The mission of 'enabling earlier diagnosis and more precise treatment for every blood vessel',"Accelerate product iteration and upgrading, deepen international layout, and strive to build an AI + surgical robot integrated hardware and software platform for intelligent diagnosis and treatment of coronary heart disease, bringing more smart medical solutions to patients and healthcare workers in more regions around the world.